Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression
Open Access
- 20 April 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (8) , 1628-1639
Abstract
The oncogenic drivers and progression factors in multiple myeloma (MM) are heterogeneous and difficult to target therapeutically. Many different MM drugs have emerged, however, that attack various phenotypic aspects of malignant plasma cells. These drugs are administered in numerous, seemingly interchangeable combinations. Although the availability of many treatment options is useful, no clinical test capable of optimizing and sequencing the treatment regimens for an individual patient is currently available. To overcome this problem, we developed a functional ex vivo approach to measure patients’ inherent and acquired drug resistance. This method, which we termed myeloma drug sensitivity testing (My-DST), uses unselected bone marrow mononuclear cells with a panel of drugs in clinical use, followed by flow cytometry to measure myeloma-specific cytotoxicity. We found that using whole bone marrow cultures helped preserve primary MM cell viability. My-DST was used to profile 55 primary samples at diagnosis or at relapse. Sensitivity or resistance to each drug was determined from the change in MM viability relative to untreated control samples. My-DST identified progressive loss of sensitivity to immunomodulatory drugs, proteasome inhibitors, and daratumumab through the disease course, mirroring the clinical development of resistance. Prospectively, patients’ ex vivo drug sensitivity to the drugs subsequently received was sensitive and specific for clinical response. In addition, treatment with <2 drugs identified as sensitive by My-DST led to inferior depth and duration of clinical response. In summary, ex vivo drug sensitivity is prognostically impactful and, with further validation, may facilitate more personalized and effective therapeutic regimens.Keywords
This publication has 46 references indexed in Scilit:
- The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapiesBlood Cancer Journal, 2011
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumabHaematologica, 2010
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight reviewLeukemia, 2009
- Recent major improvement in long-term survival of younger patients with multiple myelomaBlood, 2008
- Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelomaBlood, 2007
- Glucocorticoid receptor transcriptional isoforms and resistance in multiple myeloma cellsMolecular Cancer Therapeutics, 2006
- Molecular Pathogenesis and a Consequent Classification of Multiple MyelomaJournal of Clinical Oncology, 2005
- Characterization of the MM.1 human multiple myeloma (MM) cell linesExperimental Hematology, 2003
- Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell linesImmunology, 1999
- In vitro Ig‐synthesis and proliferative activity in multiple myeloma are stimulated by different growth factorsBritish Journal of Haematology, 1991